Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.
about
Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result DatabaseUse of tomotherapy in treatment of synchronous bilateral breast cancer: dosimetric comparison study.A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancerSynchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost.Cardiac toxicity in the radiation treatment of esophageal cancer: an emerging concern.The Use of Imaging in the Prediction and Assessment of Cancer Treatment Toxicity.Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancerSymptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer.Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer.Respiratory gating and multifield technique radiotherapy for esophageal cancer.Impact of CT slice thickness on volume and dose evaluation during thoracic cancer radiotherapyChanges in cardiac volume determined with repeated enhanced 4DCT during chemoradiotherapy for esophageal cancer
P2860
Q36080134-AB423E0D-44F0-478A-B5CA-72FB6FF3AE00Q36295414-B3360872-174F-41E7-831C-563C6CF0F1F3Q36451615-521C8D6A-31AB-4B4C-8B2B-D881A260EC8BQ38948817-8C0F046B-B3EA-4FAB-AA50-7E72F0AD60E5Q38978080-2248C002-5CDC-4CC4-9E07-979D69DD18ACQ39447268-577858BD-2C2E-427D-AB5F-8FC676924CF3Q39452568-B9AC1BEF-07E1-4AF8-8C46-2EA2FB20A630Q39992067-9DF89CDC-1159-49DF-803D-DBE96E8AAEDAQ40080098-134249A7-1146-4AA3-BA40-C6BF0FA0287DQ40235388-1597782A-4839-4013-A58F-C2A66C29A1B7Q47981940-2BFCBD84-574F-42E9-B69F-EDEEB02F76B6Q57071729-75BFF117-0222-43AE-ABFE-0646A93D3904Q58725435-482F56E8-178F-4C86-9880-C4438267E155
P2860
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Symptomatic cardiac toxicity i ...... therapy for esophageal cancer.
@ast
Symptomatic cardiac toxicity i ...... therapy for esophageal cancer.
@en
type
label
Symptomatic cardiac toxicity i ...... therapy for esophageal cancer.
@ast
Symptomatic cardiac toxicity i ...... therapy for esophageal cancer.
@en
prefLabel
Symptomatic cardiac toxicity i ...... therapy for esophageal cancer.
@ast
Symptomatic cardiac toxicity i ...... therapy for esophageal cancer.
@en
P2093
P2860
P1476
Symptomatic cardiac toxicity i ...... therapy for esophageal cancer.
@en
P2093
Alan Maurer
Andre Konski
Gary M Freedman
Jeffrey Tokar
Jonathan D Cheng
Kevin Crawford
Michael Christensen
Neal J Meropol
Oleh Haluszka
P2860
P356
10.1016/J.RADONC.2012.04.016
P577
2012-06-07T00:00:00Z